Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals | Statement: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals]

Target entity: ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals
Context triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals]

• A. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• B. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
  ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
• C. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
  ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
• D. ICH Q1 Stability Testing of New Drug Substances and Products
  ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
• E. Certificates of Suitability to the monographs of the European Pharmacopoeia
  Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals
Triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals]

ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals is an international guideline that outlines the core nonclinical safety pharmacology studies needed to evaluate the potential undesirable effects of new drugs on vital physiological functions before human use.

Target entity: ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals
Target entity description: ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals is an international guideline that outlines the core nonclinical safety pharmacology studies needed to evaluate the potential undesirable effects of new drugs on vital physiological functions before human use.

• A. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• B. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
  ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
• C. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
  ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
• D. ICH Q1 Stability Testing of New Drug Substances and Products
  ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
• E. Certificates of Suitability to the monographs of the European Pharmacopoeia
  Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
• F. None of above. chosen